Fluoxetine–Aripiprazole Pharmacokinetic Interaction
Fluoxetine is a strong CYP2D6 inhibitor, and coadministration with aripiprazole increases aripiprazole exposure (plasma concentrations). [1] The increased aripiprazole exposure can increase the probability of adverse effects, including akathisia and extrapyramidal symptoms. [1] Aripiprazole dosing should be reduced with CYP2D6 inhibitors for most indications, with a specific exception for major depressive disorder augmentation. [1]
Medication Selection Algorithm
Aripiprazole exposure is increased by CYP2D6 inhibitors (fluoxetine and paroxetine). [1]
- Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine): aripiprazole dose reduction is recommended. [1]
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): aripiprazole dose reduction is recommended. [1]
- Concomitant strong CYP3A4 and strong CYP2D6 inhibition: aripiprazole dose reduction to a quarter of usual dose is recommended. [1]
Dose–Level Relationship
Fluoxetine increases aripiprazole exposure via CYP2D6 inhibition. [1] The aripiprazole labeling provides dose-adjustment recommendations based on inhibitor strength rather than a specific fluoxetine dose-to-concentration conversion. [1] Steady-state CYP2D6 inhibition by SSRIs has been demonstrated in pharmacokinetic studies using fluoxetine/paroxetine-class inhibitors, with changes in aripiprazole clearance consistent with CYP2D6 inhibition. [2]
Dosing Recommendations With Fluoxetine
Aripiprazole labeling states that when aripiprazole is given with potential CYP2D6 inhibitors such as fluoxetine, the aripiprazole dose should be reduced to at least half of the normal dose. [1] When a CYP2D6 inhibitor is withdrawn, the aripiprazole dose should be increased back to the previous level. [1] When adjunctive aripiprazole is used for major depressive disorder with concurrent antidepressant therapy, aripiprazole should be administered without the specified dosage adjustment. [1]
Efficacy Implications
Aripiprazole dose reductions are intended to achieve a favorable clinical response after exposure changes from CYP2D6 inhibition. [1] A direct evidence-based link between the degree of concentration increase from fluoxetine and incremental efficacy is not specified in the aripiprazole labeling. [1]
Side Effect Risk and Clinical Monitoring
Coadministration with strong CYP2D6 inhibitors increases aripiprazole concentrations, which can increase adverse-effect risk. [1] Akathisia-related events occurred more frequently with adjunctive aripiprazole versus adjunctive placebo in major depressive disorder trials (25% vs 4%). [1] Akathisia-related events were also reported more frequently than placebo in bipolar mania trials (for example, 13% vs 4% for monotherapy; and 15% vs 8% for adjunctive therapy with lithium or valproate). [1] Dose-related adverse reactions were described for somnolence in schizophrenia trials, with higher incidence reported at the 30 mg dose versus lower doses and placebo. [1]
Common Pitfalls to Avoid
The aripiprazole dose reduction rule should not be applied to the major depressive disorder augmentation indication described in labeling. [1] Aripiprazole dose increases should not be delayed after fluoxetine discontinuation, because aripiprazole exposure can decrease when CYP2D6 inhibition resolves. [1] Unrecognized CYP2D6 inhibition from fluoxetine can result in an effectively higher aripiprazole dose due to higher exposure. [1]
Practical Adjustment Framework
Aripiprazole dosing should be reduced when fluoxetine is used concurrently, using at least a half-dose reduction for CYP2D6 inhibition. [1] When strong CYP3A4 inhibition is also present, aripiprazole dose reduction can be larger (to one-quarter of usual dose) based on labeling. [1] Clinical response and tolerability should guide subsequent dose adjustment. [1]